ClassID:

96707

C07K5/0804 - CPC Classification

Classification description:

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Tripeptides with the first amino acid being neutral and aliphatic

Sub-classes:
Recent Application in this class:
#1
20250026786
2025-01-23

PEPTIDE-CONTAINING COMPOSITION

#2
20240002896
2024-01-04

PEPTIDE TAG AND TAGGED PROTEIN CONTAINING SAME

#3
20230257400
2023-08-17

METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES

#4
20230133667
2023-05-04

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

#5
20220409779
2022-12-29

BRONCHIAL EMBOLIZATION MATERIAL

#6
20220315623
2022-10-06

Cyclic peptide compound simulating natural product structure, and method for preparation thereof

#7
20220227806
2022-07-21

HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS

#8
20220211797
2022-07-07

Inhibitors of IAP

#9
20220009965
2022-01-13

PEPTIDE INHIBITORS OF TIGHT JUNCTION PERMEABILITY

#10
20210198316
2021-07-01

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

#11
20210171547
2021-06-10

METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES

#12
20210171546
2021-06-10

Methods of preparing cytotoxic benzodiazepine derivatives

#13
20200231626
2020-07-23

Peptide inhibitors of tight junction permeability

#14
20200024309
2020-01-23

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

#15
20200017526
2020-01-16

METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES

#16
20190389883
2019-12-26

Methods of preparing cytotoxic benzodiazepine derivatives

#17
20190263858
2019-08-29

Compounds

#18
20190224269
2019-07-25

Inhibitors of IAP

#19
20190127419
2019-05-02

Neuropeptide S receptor (NPSR) agonists

#20
20190112320
2019-04-18

Methods of preparing cytotoxic benzodiazepine derivatives

#21
20190010169
2019-01-10

Methods of preparing cytotoxic benzodiazepine derivatives

#22
20180371016
2018-12-27

Trifluoromethylpropanamide derivatives as HTRA1 inhibitors

#23
20180371014
2018-12-27

CHIRAL COMPOUNDS OF VARYING CONFORMATIONAL RIGIDITY AND METHODS OF SYNTHESIS

#24
20180201626
2018-07-19

Methods of preparing cytotoxic benzodiazepine derivatives

#25
20180134750
2018-05-17

Inhibition of gliadin peptides

#26
20180057528
2018-03-01

Indoline compounds as granzyme B inhibitors

#27
20170096451
2017-04-06

INHIBITION OF GLIADIN PEPTIDES

#28
20170071907
2017-03-16

Thieno-indole moieties and methods of treating using the same

#29
20170051011
2017-02-23

Methods of preparing cytotoxic benzodiazepine derivatives

#30
20170050986
2017-02-23

Methods of preparing cytotoxic benzodiazepine derivatives

#31
20170050985
2017-02-23

Methods of preparing cytotoxic benzodiazepine derivatives

#32
20160317605
2016-11-03

Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers

#33
20160243249
2016-08-25

HCV protease inhibitors and uses thereof

#34
20160102119
2016-04-14

Inhibitors of IAP

#35
20160083422
2016-03-24

Indoline compounds as granzyme B inhibitors

#36
20150266897
2015-09-24

HCV NS3 protease inhibitors

#37
20150252073
2015-09-10

Peptides having NF-κB inhibitory activity, or composition comprising same

#38
20150239930
2015-08-27

Hepatitis C virus inhibitors

#39
20150203537
2015-07-23

INHIBITION OF GLIADIN PEPTIDES

#40
20150175657
2015-06-25

HCV protease inhibitors and uses thereof

#41
20150125422
2015-05-07

Hepatitis C virus inhibitors

#42
20150119342
2015-04-30

Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers

#43
20150104485
2015-04-16

Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions

#44
20150051154
2015-02-19

Thieno-indole moieties and methods of treating using the same

#45
20150031633
2015-01-29

Bifunctional peptide

#46
20140336115
2014-11-13

Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity

#47
20140296136
2014-10-02

HCV NS3 protease inhibitors

#48
20140271488
2014-09-18

Chiral oligomeric pentenoate amides as bio-oligomer mimetics

#49
20140235551
2014-08-21

Inhibitors of IAP

#50
20140213758
2014-07-31

Versatile native chemical ligation technologies

#51
20140127156
2014-05-08

Hepatitis C virus inhibitors

#52
20140018518
2014-01-16

Crystaline forms of HCV inhibitor

#53
20130338062
2013-12-19

HCV protease inhibitors and uses thereof

#54
20130115190
2013-05-09

Hepatitis C virus inhibitors

#55
20130053577
2013-02-28

Antiviral compounds

#56
20130017991
2013-01-17

HCV protease inhibitors and uses thereof

#57
20120322722
2012-12-20

Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use

#58
20120251493
2012-10-04

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

#59
20120208995
2012-08-16

Macrocyclic inhibitors of hepatitis C virus replication

#60
20120190866
2012-07-26

Antiviral compounds

#61
20120190614
2012-07-26

HCV protease inhibitors and uses thereof

#62
20120172291
2012-07-05

Macrocyclic hepatitis C serine protease inhibitors

#63
20120121624
2012-05-17

Hepatitis C virus NS3 protease inhibitors

#64
20120101032
2012-04-26

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

#65
20120014914
2012-01-19

Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases

#66
20110300147
2011-12-08

Inhibiting tumor cell invasion, metastasis and angiogenesis

#67
20110294778
2011-12-01

HEPATITIS C INHIBITOR COMPOUNDS

#68
20110275562
2011-11-10

Inhibition of gliadin peptides

#69
20110269696
2011-11-03

Inhibitors of IAP

#70
20110263844
2011-10-27

METHOD FOR PREPARING MACROCYCLES

#71
20110182854
2011-07-28

HCV protease inhibitors

#72
20110165120
2011-07-07

Inhibitors of serine proteases

#73
20110129444
2011-06-02

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

#74
20110105389
2011-05-05

Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same

#75
20110081315
2011-04-07

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

#76
20110065737
2011-03-17

HCV protease inhibitors

#77
20110046161
2011-02-24

HCV NS3 protease inhibitors

#78
20100323953
2010-12-23

MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS

#79
20100272674
2010-10-28

Hepatitis C Virus Inhibitors

#80
20100240638
2010-09-23

Organic Compounds and their uses

#81
20100168384
2010-07-01

Anti-viral compounds

#82
20100113326
2010-05-06

DIMERIC IAP INHIBITORS

#83
20100099695
2010-04-22

HCV NS3 Protease Inhibitors

#84
20100081700
2010-04-01

Hepatitis C virus inhibitors

#85
20100069294
2010-03-18

HCV protease inhibitors and uses thereof

#86
20100041674
2010-02-18

HCV protease inhibitors and uses thereof

#87
20100041591
2010-02-18

HCV protease inhibitors and uses thereof

#88
20100015092
2010-01-21

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

#89
20090297472
2009-12-03

Hepatitis C virus inhibitors

#90
20090286843
2009-11-19

MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

#91
20090286814
2009-11-19

HCV PROTEASE INHIBITORS

#92
20090274648
2009-11-05

Hepatitis C virus inhibitors

#93
20090270618
2009-10-29

Phosphonyl ester conjugates as prodrugs

#94
20090257978
2009-10-15

Antiviral compounds

#95
20090186869
2009-07-23

Antiviral compounds

#96
20090175873
2009-07-09

Inhibiting tumor cell invasion, metastasis and angiogenesis

#97
20090169510
2009-07-02

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

#98
20090156800
2009-06-18

Process for making macrocyclic oximyl hepatitis C protease inhibitors

#99
20090148407
2009-06-11

Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication

#100
20090130059
2009-05-21

Tetrazolyl macrocyclic hepatitis C serine protease inhibitors

#101
20090111982
2009-04-30

MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

#102
20090111969
2009-04-30

MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

#103
20090105471
2009-04-23

MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

#104
20090047252
2009-02-19

Antiviral compounds

#105
20090041721
2009-02-12

Arylalkoxyl hepatitis C virus protease inhibitors

#106
20090022688
2009-01-22

INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE

#107
20080181868
2008-07-31

Macrocylic oximyl hepatitis C protease inhibitors

#108
20080152622
2008-06-26

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

#109
20080125376
2008-05-29

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

#110
20080107625
2008-05-08

Inhibitors of Hepatitis C Virus

#111
20080107624
2008-05-08

Inhibitors of hepatitis C virus

#112
20080107623
2008-05-08

Inhibitors of Hepatitis C Virus

#113
20080039375
2008-02-14

Phosphorus-containing hepatitis C serine protease inhibitors

#114
20080038225
2008-02-14

TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

#115
20070281885
2007-12-06

Macrocylic oximyl hepatitis C protease inhibitors

#116
20070281884
2007-12-06

Macrocyclic oximyl hepatitis C protease inhibitors

#117
20070249637
2007-10-25

Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same

#118
20070232549
2007-10-04

Peptides as NS3-serine protease inhibitors of hepatitis C virus

#119
20070197448
2007-08-23

Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease

#120
20070179167
2007-08-02

Inhibitors of serine proteases

#121
20070099825
2007-05-03

Hepatitis C virus inhibitors

#122
20070093414
2007-04-26

Hepatitis C virus inhibitors

#123
20070060510
2007-03-15

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

#124
20070054865
2007-03-08

Anti-inflammatory peptides

#125
20070054842
2007-03-08

Macrocyclic inhibitors of hepatitis C virus replication

#126
20070032433
2007-02-08

Peptides as NS3-serine protease inhibitors of hepatitis C virus

#127
20060287248
2006-12-21

Asymmetric dosing methods

#128
20060257980
2006-11-16

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

#129
20060111276
2006-05-25

Cidofovir peptide conjugates as prodrugs

#130
20060063916
2006-03-23

Process for preparing macrocyclic HCV protease inhibitors

#131
20060063915
2006-03-23

Ring-closing metathesis process in supercritical fluid

#132
20050267018
2005-12-01

Macrocyclic compounds as inhibitors of viral replication

#133
20050215423
2005-09-29

Process of removing transition metals

#134
20050090450
2005-04-28

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

#135
20050090432
2005-04-28

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

#136
20050080017
2005-04-14

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

#137
20050049187
2005-03-03

Process for preparing macrocyclic compounds